Commit Biologics launches with €16m seed financing to pioneer complement system activation to treat cancer and autoimmune disease
- Financing led by Bioqube Ventures and Novo Holdings
- Commit is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases
- Its unique bispecific technology (BiCE™) engages the complement system, unleashing its power to selectively kill target cells
- Spin-out from Aarhus University in Denmark, a world leader in complement structural biology
Aarhus, Denmark – 9 May 2024 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today exits from stealth with €16m in seed funding from Bioqube Ventures and Novo Holdings.
